Amylyx Pharmaceuticals, Inc. (AMLX) Stock
Key stats
- Market cap
- $3.59B
- Price / Earnings ratio
- -21.3x
- EPS (TTM)
- -$13.35
- Volume
- Loading
- 52-week high
- $41.14
- 52-week low
- $10.83
- Next earnings report
- 5 Nov 2026
Source: third-party data provider, as of October 24, 2026
Compare with AMLX
Recent news

Amylyx Pharmaceuticals to Present Topline Data from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek® 2026 Annual Meeting
Amylyx Pharmaceuticals to Present Topline Data from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek® 2026 Annual Meeting
AMLX

Amylyx's Avexitide Phase III Win Sets Up FDA Filing for PBH Treatment
Amylyx's Avexitide Phase III Win Sets Up FDA Filing for PBH Treatment
AMLX

Amylyx Pharmaceuticals to Present at the Stifel 2026 Virtual Cardiometabolic Forum
Amylyx Pharmaceuticals to Present at the Stifel 2026 Virtual Cardiometabolic Forum
AMLX

Amylyx Pharmaceuticals to Present at the 24th Annual Morgan Stanley Global Healthcare Conference
Amylyx Pharmaceuticals to Present at the 24th Annual Morgan Stanley Global Healthcare Conference
AMLX
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 48.96
- MACD 12/26/9
- -0.62
- EMA 9 of MACD
- -0.82
- MACD histogram
- 0.20
- SMA 50
- $31.11
- Price below SMA 50
- EMA 50
- $28.33
- Price above EMA 50
- SMA 200
- $19.61
- Price above SMA 200
- EMA 200
- $21.32
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of October 22, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 5 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of -$0.39 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news

Amylyx Pharmaceuticals to Present Topline Data from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek® 2026 Annual Meeting
Amylyx Pharmaceuticals to Present Topline Data from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek® 2026 Annual Meeting
AMLX

Amylyx's Avexitide Phase III Win Sets Up FDA Filing for PBH Treatment
Amylyx's Avexitide Phase III Win Sets Up FDA Filing for PBH Treatment
AMLX

Amylyx Pharmaceuticals to Present at the Stifel 2026 Virtual Cardiometabolic Forum
Amylyx Pharmaceuticals to Present at the Stifel 2026 Virtual Cardiometabolic Forum
AMLX

Amylyx Pharmaceuticals to Present at the 24th Annual Morgan Stanley Global Healthcare Conference
Amylyx Pharmaceuticals to Present at the 24th Annual Morgan Stanley Global Healthcare Conference
AMLX

Is GLP-1 Stock Amylyx Still a Buy After Skyrocketing 247%?
Is GLP-1 Stock Amylyx Still a Buy After Skyrocketing 247%?
AMLX

Why Amylyx Pharmaceuticals Blasted Nearly 79% Higher This Week
Why Amylyx Pharmaceuticals Blasted Nearly 79% Higher This Week
AMLX

Why Did IOVA, AMLX And COP Stocks Surge To 52-Week Highs Today?
Why Did IOVA, AMLX And COP Stocks Surge To 52-Week Highs Today?
AMLX

Amylyx Pharmaceuticals Announces Pricing of an Upsized $500 Million Underwritten Public Offering of Common Stock
Amylyx Pharmaceuticals Announces Pricing of an Upsized $500 Million Underwritten Public Offering of Common Stock
AMLX

AMLX Rises as Avexitide Nears 2026-End Filing With Phase III Study Win
AMLX Rises as Avexitide Nears 2026-End Filing With Phase III Study Win
AMLX

Dow, S&P 500, Nasdaq Futures Slip As Global Bond Rout Catches Up With Markets: LUNR, MSTR, WYFI, AMLX Stocks In Focus
Dow, S&P 500, Nasdaq Futures Slip As Global Bond Rout Catches Up With Markets: LUNR, MSTR, WYFI, AMLX Stocks In Focus
AMLX
News tone: automated (AI) classification of the article's content, not a price prediction.
About Amylyx Pharmaceuticals, Inc.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Joshua B. Cohen | Co-Founder, Co-CEO & Director | 1992 |
| Mr. Justin B. Klee | Co-CEO & Director | 1991 |
| Mr. James M. Frates M.B.A. | Chief Financial Officer | 1967 |
| Dr. Camille L. Bedrosian M.D. | Chief Medical Officer | 1953 |
| Mr. Tom Holmes | Chief Technical Operations Officer | — |
| Ms. Lindsey Allen | Head of Investor Relations & Communications | — |
| Ms. Gina M. Mazzariello J.D. | Chief Legal Officer & General Counsel | 1972 |
| Ms. Linda A. Arsenault | Chief Human Resources Officer | — |
| Ms. Tammy Sarnelli | Global Head of Regulatory Affairs | — |
| Dr. Machelle Manuel Ph.D. | VP & Head of Global Medical Affairs | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of October 24, 2026
Technical indicators
- RSI 14
- 48.96
- MACD 12/26/9
- -0.62
- EMA 9 of MACD
- -0.82
- MACD histogram
- 0.20
- SMA 50
- $31.11
- Price below SMA 50
- EMA 50
- $28.33
- Price above EMA 50
- SMA 200
- $19.61
- Price above SMA 200
- EMA 200
- $21.32
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of October 22, 2026. Technical data, not a recommendation.
Analyst views
5 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $39.00
- Average
- $49.00
- High
- $57.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022 | +28.3 | +40.8 | -54.2 | -30.1 | -2.6 | +125.3 | +38.6 | -2.2 | +19.6 | +19.9 | +7.0 | -5.9 |
| 2023 | +8.9 | -11.6 | -14.2 | -0.7 | -13.3 | -11.8 | +11.8 | -7.8 | -16.1 | -10.0 | -17.2 | +3.5 |
| 2024 | +6.9 | +13.8 | -84.8 | -33.2 | -10.9 | +11.8 | +9.6 | +7.2 | +50.0 | +76.5 | -1.8 | -31.9 |
| 2025 | -6.6 | -4.1 | +18.0 | +53.0 | +0.2 | +25.7 | +25.3 | +21.5 | +36.2 | -0.5 | +10.1 | -15.2 |
| 2026 | +25.1 | +3.4 | -9.2 | +11.5 | -10.4 | +27.6 | +13.1 | +67.3 | -13.9 | +1.7 |



